The first effective therapy for exudative macular degeneration (AMD) was Photodynamic Therapy (PDT). Diagnosis of the disease was to a large extent by fluorescein angiography (FA). Distinguishing between the leaky choroidal neovessels (CNV) associated with exudative AMD, and the polypoidal structures associated with Polypoidal Choroidal Vasculopathy (PCV) is not always easy using FA alone. The switch to Indocyanine Green angiography helped to pinpoint PCV, and thus to study the efficacy of photodynamic therapy of this particular form of retinal disease, which is more frequently encountered among pigmented individuals. The results appear to be quite promising, and in the year following treatment only a small fraction of the patients had to be retreated. Alternatively, treating PCV with repeated intravitreal VEGF blocking agents was not as successful as it was in the treatment of wet AMD. However, combining PDT-induced angio-occlusion of the polypoidal lesions with anti-vascular endothelial growth factor therapy was shown to be quite effective, and the combination of PDT with an anti-angiogenic agent as well as a steroid, in a triple therapy, was recently also shown to be a quite promising option. In the present article we review the data on PDT of PCV, including combination therapies and alternative treatments. We also report on similarities and differences between AMD and PCV.
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Introduction
Photodynamic therapy (PDT) was introduced in ophthalmology in the late 1990s as a treatment for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (Schmidt-Erfurth et al., 1998; van den Bergh, 2001) . PDT with Visudyne Ò as a photosensitizer was the first effective and safe treatment for subfoveal lesions, saving up to now more than a million eyes from legal blindness Bressler et al., 2002; Bressler and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study, 2001 ). CNV is encountered in patients with exudative AMD, but also occurs in pathologic myopia, inflammation, angioid streaks, trauma and choroidal rupture (Koh et al., 2011; Koh and Haimovici, 2004) . Although wet AMD constitutes only a small fraction (10%e15%) of AMD, it is the major cause of blindness of the elderly in the western world (Ambati et al., 2003) . CNV often develops in or near the fovea, the central part of the macula, where the leaking vessels lead to edema, and finally scar tissue, which may replace the photoreceptors. The maintenance of healthy macular function is dependent on the integrity of the different layers of the retina and the associated functional biochemical processes. These layers include the choroid, Bruch's membrane, the retinal pigmented epithelium (RPE), the photoreceptors and Müller cells, and the neural retina which preprocesses the visual information, before sending it via the ganglion cells, the axons, the optic nerve and the lateral geniculate nucleus, to the visual cortex of the brain. The etiology of CNV secondary to AMD is still not completely known (Kevany and Palczewski, 2010; Young, 1967) . The photoreceptor outer segments that include a stack of phospholipid membrane discs containing the opsins, which are responsible for the initiation of phototransduction, and which accumulate oxidative stress in the vision process. A key component in this photo-oxydation being alltrans-retinal, an intermediate in the visual retinoid cycle, which interacts with UV and blue light to produce reactive oxygen species (ROS) including O 2 À , O 2 1 D and peroxides. These ROS react with proteins and lipids changing their chemical structure and hence their function (Maeda et al., 2012) . Part of these outer segments contains many discs that are then periodically shed. The shed outer segment (OS) fragments are then phagocytosed and destroyed by lysosomal degradation in the neighboring RPE cells. The oxidized compounds are less well degraded by the lysosomal enzymes, which leads to deposits of a fatty material called lipofuscin in and under the RPE. Such deposits, consisting of among others retinoid conjugates may show up as whitish spots during ophthalmoscopy, are called drusen. Blue light excitation of lipofuscin can lead to further oxidation, which may induce inflammation and angiogenesis. Also the decreased transport of oxygen, liquid and nutrients due to these lipophilic deposits can lead to hypoxia, the induction of HIF-1a (hypoxia-inducible factor 1-alpha) and VEGF-A (vascular endothelial growth factor-A) and hence neo-angiogenesis and vascular sprouting from the choroid into Bruch's membrane. Some of the possible causes for the accumulation of toxic pigments in and around the RPE that are related to defects in the visual retinal cycle taking place both in rods and cones, are shown schematically in Fig. 1 for the case of rod opsin (Kevany and Palczewski, 2010; Travis et al., 2007; Young, 1967) . This cycle is based on the photo-isomerization of 11-cis-retinaldehyde (11-cis-RAL), the main visual chromophore, to all-trans-RAL, which leads to conformational changes in rhodopsin. This, in the end, leads to activation of the phototransduction cascade. The all-trans-RAL must then be recycled to 11-cis-RAL in order to restore the visual pigment, otherwise vision would not be maintained. This recycling, in the case of rod photoreceptors, starts in the outer segments, and then goes via the RPE cells back into the rods. The cone retinal cycle needs to be much faster than in the case of rods, i.e. up to 10 6 /sec for the replacement of 11-cis-RAL, but its exact mechanism still needs to be confirmed (Wang and Kefalov, 2011) . It probably involves retinoid cycling from the cone outer segment to a neighboring Müller cell, and then via the cone inner segment back to the cone outer segment. In parallel, another retinoid cone cycle also starts in the cone outer segment, but passes via a number of processes in the neighboring RPE back to the cone outer segment. Another important difference between the two types of photoreceptors is that rod discs are separated from the interphotoreceptor matrix by the rod plasma membrane. The cone discs communicate more directly with this interphotoreceptor space. This morphologic difference yields a more open structure and an increased outer surface of the cone discs, which helps to enhance the rates of exchange between cone and close lying RPE and Müller cells. All these retinal cycles involve a number of enzymes for the necessary chemical and conformational changes, as well as important transport proteins (Almasieh et al., 2012; Saari, 2012; Wielgus and Roberts, 2012) . Mutations that influence these enzymes and transport proteins, can change the flow of the retinoids and cause the accumulation of toxic retinoids, as well as byproducts, thus leading to variety of agerelated and other diseases. The currently unknown etiology of Polypoidal Choroidal Vasculopathy (PCV) may well include, among others, disrupted retinoid cycling, possibly in relation to genetic mutations causing changes in the enzymes or proteins involved in this cycling process. As a number of genetic alterations that correlate with PCV are now becoming known, and are reported on below, urgent animal experiments are needed to investigate this.
Choroidal vessels are often classified as "occult" CNV when they are restricted to the area in and around Bruch's membrane, below the RPE. These are associated with more gradual leakage and slower loss of vision than is the case for the co-called "classic" CNV. The occult CNV are also relatively harder to visualize during fluorescein angiography, due to the fact that the excitation and emission wavelengths are strongly absorbed by the melanin in the RPE. Alternatively the CNV are sometimes capable of transgressing the RPE (Koh et al., 2011) , thus making them more visible in fluorescein angiography. These CNV are often associated with optically welldefined areas of leaking blood vessels that are called "classic" CNV. They are visible early-on in the fluorescein angiography, and are involved in the more severe and faster vision loss. All CNV are pathologically and functionally abnormal, leaking lipids, fluid and blood into the surrounding retina, causing edema and retinal thickening which can be observed and quantified in highresolution optical coherence tomography (OCT), and is often associated with vision impairment.
If the CVN leakage extends over longer times it can lead to scar tissue in the retina and scotoma, i.e. dark regions in our central vision. The size and number of drusen can be correlated with disease progression and has been used as a predictor for patient outcome (Liu et al., 2011) . CNV and its treatment by Visudyne Ò -photodynamic therapy (V Ò -PDT) have been described extensively in the literature (Jirarattanasopa et al., 2012; Miller, 2010; SchmidtErfurth et al., 1994 SchmidtErfurth et al., , 1998 van den Bergh, 2001 ). The results of CNV treatment with PDT alone in clinical trials, or of PDT in combination with other treatment modalities, are described in detail elsewhere . This cycle is essential to sustain continuous vision. It replenishes the main visual chromophore 11-cis-retinaldehyde (11-cis-RAL), which is bleached by visible and UV light. The replenishment is a cyclic process, which involves a number of enzymes and transport proteins. More precisely, light activation of rhodopsin, located in the discs of the outer segment of the rod cell, causes the isomerization of 11-cis-RAL to all-trans-RAL. This in turn activates the opsin, which after some conformational changes yields metarhodopsin II (MII). This induces further processes that lead to hyperpolarization of the rod cell and the visual transduction cascade. After deactivation of the MII, it separates into apo-opsin and an all-trans-RAL molecule. The latter is released in the inner leaflet of the disc bilayer where it can reversibly complex with phosphatidylethanolamine (PE) to yield retinylidene-PE (N-ret-PE), which is then "flipped" across the disc membrane by the transporter ABCA4. The all-trans-retinal can now be released from N-ret-PE to the rod cytoplasm. The all-trans-RAL itself can likewise be transported from the intradiscal space to the rod cytoplasm by ABCA4 where it is reduced by all-trans retinol dehydrogenase enzymes (all-trans-RDH's) to the alcohol (all-trans-ROL) with the help of NADPH. All-trans-ROL then moves out of the rod cell, binds to a protein (IRBP) to avoid degradation in the extracellular space before being endocytosed into an RPE cell, where it binds strongly to another protein (CRBPI). The alcohol is then esterified to all-trans-retinal-ester (all-trans-RE) by LRAT (lecithin-retinol acyl transferase). This all-trans-RE in the RPE cells can be increased to some extend by (i) all-trans-retinol (vitamin A) diffusing from the choroidal capillaries, and by (ii) all-trans-ROL from the above-mentioned phagocytosis of the shed outer segment fragments. All-trans-ROL from, both of these pathways can be esterified by LRAT to all-trans-RE. The all-trans-REs in the RPE cells are regarded as one of the "reserves" of retinoids in the visual cycle. Then a single enzyme (Rpe65) accomplishes both the trans-to-cis isomerization, as well as the hydrolysis, of the esters, to yield 11-cis-retinol, which binds to a protein (CRALBP) to avoid self-inhibition of the reaction by the cis-alcohol product. The 11-cis-ROL bound to CRALBP can then either be esterified by LRAT to form another form of retinoid cycle storage, as the cis-ester, or it can be oxidized to 11-cis-RAL by a dehydrogenase (RDH) with the help of the co-factor NAD. The 11-cis-RAL then leaves the RPE, combines with IRBP for protection and re-enters the rod cell to complete the cycle by joining with the apo-opsin thus reforming the visual pigment. This "stored" reserve of 11-cis-RE in the RPE cell can when necessary be returned to the retinoid cycle by reaction with the ester hydrolase 11-cis-REH. The main reason for giving the above somewhat detailed description of the retinoid cycle is that at every step in this cycle things can go wrong and each error may lead to a specific disease. The red arrows indicate one example of such a damage pathway, where under increased light conditions more all-trans-RAL is produced so that N-ret-PE combines more often with a second all-trans-RAL to form A2PE and finally the fluorescing product A2E. This molecule may end up in the lipofuscin deposits ("drusen") that are often associated with retinal damage. The second (thicker) red arrow pathway leading towards "DAMAGE" implies directly the all-trans-RAL. Enough of this molecule needs to be present to sustain the retinoid visual cycle. However an excess of all-trans-RAL is closely correlated with retinal degeneration. Reduced clearance of all-trans-RAL from the rod OS, for instance by insufficient activity of the all-trans-RDH enzymes, may lead to enhanced production of A2E and lipofuscin. Enhanced levels of free-trans-RAL, which produces ROS when activated by UV/blue light, furthermore induces OS disc oxidation, leading to decreased lysosomal degradation of the phagocytosed discs in the RPE, and build-up of lipofuscin. Photolysis of the latter can finally lead to the release of pro-inflammatory and pro-angiogenic factors, and blinding disease. The blue arrows indicate the normal retinoid cycle with associated proteins and enzymes. The gray arrows indicate the storage of 11-cis-RE. Adapted from Maeda et al. (2006) ; Nowak-Sliwinska (2012); Travis et al. (2007) . * ) As there are significant differences between the light sensitivity and response time of rods and cones, the mechanism of the visual retinoid cycle is also bound to show differences between these two kinds of photoreceptors, i.e. cycling must be significantly faster in cones. Here we show some details of the retinoid recycling between rods and RPE cells only, as the recycling mechanism for cones is less well established. It has been suggested to include Müller cells, as well as RPE cells, see also (Travis et al., 2007; Wang and Kefalov, 2011) . MONT BLANC V Ò -PDT*; vs. ranibizumab 0.5 mg 12 VA improvements in the combination group are non-inferior to a ranibizumab alone with three ranibizumab doses followed by injections on a monthly regimen. (Antoszyk et al., 2008; Augustin, 2009; Bertossi et al., 1999; Blinder et al., 2003; Hudson, 2008; Kaiser, 2006; Lam et al., 2004; Lee et al., 2008b; Schmidt-Erfurth et al., 2008; Spitzer et al., 2008; Yip et al., 2009) and are summarized in Table 1 . While comparing the clinical trial results obtained in the treatment of what was thought to be the CNV associated with exudative AMD, significant differences in the visual acuity outcome were observed between Asian and Caucasian patients. In fact, the responses to photodynamic therapy were better in Japanese patients (JAT trial) as compared to Caucasian patients (TAP trial) (2003), see Fig. 2 . Exactly the same therapy (same drug, same injections, same drug-light interval, same light fluence and intensity, same patient inclusion/exclusion criteria, same way of evaluation the VA, etc.) in Japanese patients diagnosed with exudative AMD gave better visual acuity gain vs. sham than in the Caucasian patients that had also been diagnosed with exudative AMD Negrier and Raymond, 2012; Yamashita et al., 2010) .
Historically, with the use of indocyanine green angiography (ICGA) atypical cases of AMD had been found, with a vascular network that terminates in polypoidal lesions. These lesions were called polypoidal choroidal vasculopathy (PCV). PCV was recognized and reported for the first time in 1982 by Yannuzzi and colleagues as an uncommon hemorrhagic disorder of the macula (Ciardella et al., 2004) . Two years later similar retinal changes named "posterior uveal bleeding syndrome" were observed by Kleiner et al. (Kleiner et al., 1990) . In 1985, Stern and colleagues characterized multiple, bilateral, serosanguineous retinal pigment epithelium detachments occurring in African woman (Stern et al., 1985) . Five years later Yannuzzi and collaborators introduced the term "idiopathic PCV", since the observed pathogenesis of subretinal, polypoidal vascular lesions associated with hemorrhagic RPE detachments was at that time unknown (Yannuzzi et al., 1997) . , irradiance of 600 mW/cm 2 of 689 nm light over 83 s, starting 15 min after the beginning of the i.v. infusion) produces a vaso-occlusive effect. CNV damage from PDT generally depends on the photosensitizing agent and the treatment regimen used. Photodynamic damage caused by illumination of a PS shortly after its injection is mostly observed in the endothelium and subendothelium (van den Bergh and Ballini, 2003) . The endothelial cell damage, originates at the endothelial luminal surface and begins with the influx of calcium into the cells (Foster et al., 1991) . This increase in the cytosolic calcium concentration leads to conformational changes in adhesion molecules and modifications in the cytoskeleton, such as the depolarization of cytoplasmic microtubules. This is followed by cell shape alterations, such as rounding and contraction (Nelson et al., 1987) . Contraction of endothelial cells results in the loss of tight junctions between these cells and the exposure of the vascular basement membrane (Schmidt-Erfurth et al., 1994) to circulating blood, and the local activation of von Willebrand factor (vWf). The subsequent interaction of blood platelets with the denudated vascular wall induces the activation and aggregation of platelets. Platelets have also been shown to accumulate PSs and upon irradiation are damaged, losing serotonin and ATP proportional to the PS dose administered Zieve et al.,1966) . In the end, platelet damage and the interaction of platelets with pro-coagulant extracellular matrix components and the damage to the endothelium lead to vessel constriction and thrombus formation via Ca 2þ exchange between pericytes and the endothelium (Henderson et al., 1992; Nelson et al., 1987; Reed et al., 1988) . The adhesion of granulocytes has also been observed following endothelial cell damage. This can induce increased vascular permeability and edema (Fingar, 1996) . Damage to platelets further stimulates the release of thromboxane and leukotriene B4, both of which contribute to enhanced vascular permeability and the disruption of the endothelial cell lining of exposed blood vessels (Doukas et al., 1989; Klausner et al., 1989) . Endothelial cells may also influence the blood clotting balance through the release of clotting factors (Ben-Hur et al., 1988) , including vWf (Foster et al., 1991) . All of these biochemical changes disrupt the balance of platelet pro-aggregatory/vaso-constricting compounds and antiaggregatory/vaso-dilating agents (Chang and Petry, 1980; Ogletree, 1987) , resulting in smooth muscle constriction and further platelet aggregation. In a parallel mechanism, PDT-induced damage to membrane lipids elicits the release of arachidonic acid, which initiates a series of reactions, also ending in the release of thromboxane. Vessel constriction is further supported by the inhibition of nitric oxide production in endothelial cells (Gilissen et al., 1993) . Finally, a blood clot within the vessel lumen can potentially cause obstruction to blood flow (stasis), leading to the termination of vascular function. In summary, PDT depending on the applied conditions, can either lead to blockage of the vasculature, or to enhanced leakage from the vasculature, or to both. In the present application, PDT of PCV, one tries to select conditions that are optimal for the selective closure of the PCV.
The most important factor determining the outcome of PDT is how the photosensitizer interacts with the cells within the target tissue. The photosensitizers can localize in many different cellular organelles such as the mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus and plasma membranes (Pazos and Nader, 2007) . Water-soluble photosensitizers may predominantly bind to lysosomes, leading to release of cathepsins and necrosis (Hamblin and Mroz, 2008) or autophagy (Kessel and Oleinick, 2010) . Verteporfin, as a somewhat more hydrophobic compound, mainly localizes in mitochondria and at the time of light delivery generates reactive oxygen species (ROS) causing the disruption of the mitochondrial membrane. The latter probably causes the opening of the mitochondrial permeability transition pore complex (PTPC), which leads to the secretion of cytochrome-c into the cytosol. Cytochrome-c forms an apoptosom, a multi-protein complex, with apoptosis-activation factor 1 and ATP. The latter activates procaspase 9, and then the apoptosom releases caspase 9 that finally induces caspase 3, which is a key protein in the induction of apoptosis. A more detailed description can be found in van den Bergh and Ballini (van den Bergh and Ballini, 2003) or others (Hamblin and Mroz, 2008) (Robertson et al., 2009 ).
Epidemiology and clinical characteristics of polypoidal choroidal vasculopathy (PCV)
3.1. Epidemiology PCV was often found to be the main vascular disorder in patients of pigmented races diagnosed with neovascular maculopathies, especially African-Americans and Asians (Ciardella et al., 2004 ) (Wen et al., 2004) . PCV is also frequent in the Japanese population. PCV occurs in white patients (Imamura et al., 2010 ), but to a significantly lesser extent. Japanese clinical studies suggested that 54.7% of the patients with neovascular age-related macular degeneration also have PCV (Maruko et al., 2007) . The agedistribution at which PCV is diagnosed is also different from that of wet AMD. Indeed PCV is usually diagnosed in patients between 50 and 65 years old, but the age of diagnosis may range between 20 and more than 80 years. Caucasians seem to have more female cases of PCV, while in Asia it is more the male population that is affected (Kwok et al., 2002; Wen et al., 2004) . The presence of PCV in one eye generally indicates a high risk for bilateralism (Ciardella et al., 2004) .
Clinical characteristics
The main clinical characteristic of PCV is the presence of early focal nodular hyperfluorescence detected by means of indocyanine green angiography (ICGA). The latter is the gold standard for the diagnostic of this disease (Koh et al., 2012) . The longer excitation and detection wavelengths for ICG fluorescence, as compared to those used in fluorescein angiography, can penetrate the RPE easier, allowing improved imaging (see Fig. 3 ).
In early-phase ICGA, the choroidal PCV vessels are dilated (Chung et al., 2011) and the area around polypoidal vessels remains hypofluorescent. Subsequently, small hyperfluorescent polyps become visible in the choroid. The late phase ICGA is associated with reversed fluorescence observations as compared to the early phase, i.e. the area surrounding the polypoidal lesions becomes fluorescent and the center of the lesions becomes hypofluorescent (Spaide et al., 1995) .
The reason for choroidal hyperpermeability as detected by ICG angiography in PCV is still not well known. OCT images, giving a cross-sectional view of the retina and the choroid, showed that the polypoidal structures are located beneath the RPE (Iijima et al., 2000; Imamura et al., 2010) . While the branching vascular network may be quiescent in some cases of PCV, it can remain the main cause of leakage and exudation in other patients. One of the main advantages of ICGA is that ICG is highly protein bound, and the larger molecular complex does not leak easily from the choriocapillaries, allowing clear definition of the vascular structures within the choriocapillaries. Retina Angiography (RA) during the first minute transit phase, using a scanning laser ophthalmoscope (SLO) from Heidelberg allows for a clear definition of the branching vascular network, delineation of the polypoidal structures, and furthermore allows for the exclusion of retinal angiomatous proliferation (RAP). The latter is an important mimic of PCV. Lastly, ICG is used to guide the PDT treatment zone. PCV is characterized by a branching vascular network originating from the inner choroid that terminates in polypoidal lesions (Ciardella et al., 2004) . Another clinical manifestation of PCV is the presence of serosanguineous RPE detachments in the region of the central macula or around the optic nerve. These lesions may bleed, causing vitreal hemorrhage, which potentially can lead to vision loss (Fig. 4) .
PCV is usually detected only after serosanguineous detachment of the RPE, or vitreous hemorrhage, but with less fibrous scarring compared to choroidal neovascularization . Another feature is the presence of degenerated small arterioles and capillaries with a thickened basement membrane. The polypoidal lesions range from small to large and perfuse branching inner choroidal vessels (Cackett et al., 2009) .
Another feature of the PCV is a hyalinization of the choroidbased vessels. The latter refers to the replacement of smooth muscle tissue due to elevated intraluminal pressure or elastin coding gene (ELN) dysfunction (Kondo et al., 2008) . Other histopathological features included plasma and/or fibrin exudation Fig. 3 . Representative images of PCV visualized by ICG angiography (AeD). The nodular polypoidal structures are clearly shown on early ICGA within an indentation in the margin (also known as a "notch") of a large hemorrhagic pigment epithelial detachment. A hypofluorescent halo around these nodular structures is characteristic of PCV, and helpful in diagnosis when present. There is increasing hyperfluorescence through the mid and late phases of the ICGA, with late leakage and staining of the entire PCV complex. The fellow eye shows late staining from an inactive PCV complex. (Nakashizuka et al., 2008 ) associated with massive submacular hemorrhage, or associated with a branching vascular network (BVN). PCV can also be characterized by orange subretinal nodules that are visible stereoscopically in the color fundus photograph. Subfoveal choroidal thickness is greater in eyes with choroidal hyperpermeability than that in eyes without it, both in wet AMD and PCV, whereas in eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical exudative AMD (Jirarattanasopa et al., 2012) .
Identification of PCV as early as possible in the therapeutic sequence provides timely information on longer-term disease behavior and can often lead to a change in treatment strategy. OCT, giving cross-sectional images of the choroid and neural retina, helps to identify PCV by detecting the abnormalities surrounding PCV (Iijima et al., 2000) . In OCT, PCV is characterized by a higher incidence of serohemorrhagic pigment epithelium detachments (PED), greater PED height, and less intraretinal edema than eyes with exudative AMD (Ozawa et al., 2009 ). OCT images demonstrate that polypoidal structures exist beneath the RPE and they tend to be found attached to the back surface of RPE, see Table 2 (Imamura et al., 2010; Laude et al., 2010) . Thus PCV is often found in the sub-RPE space in wet AMD specimens. Giovannini et al. found in all cases reported a characteristic hyper-reflectivity in the choroidal layers (Giovannini et al., 1999) . These findings may be a key difference in the characteristics of PCV and wet AMD. Therefore, the systematic OCT scans are useful in order to provide the proper diagnosis. This might have a particular importance for already treated patients, in order to maintain the best treatment outcome during the long-term follow up period. In patients with serosanguineous detachment of the pigment epithelium, particularly those with increased risk factors, such as African-American or Asian race, ICGA and OCT should both be performed to evaluate the choroidal vascular abnormality in an attempt to establish a more definitive diagnosis.
Natural history of PCV
Polypoidal choroidal vasculopathy develops slowly and was shown to persist for a long time. Therefore the natural history of this disorder, as observed in a large series of patients was unclear (Yannuzzi et al., 1997) . In the study performed on Japanese elderly patients by Uyama et al. two patterns of the clinical manifestation of PCV were observed: exudative PCV and hemorrhagic PCV (Uyama et al., 2002) . In patients with the exudative pattern, persistent leakage and repeated bleedings leading to a poor visual outcome were observed. Serous pigment epithelial detachment (PED) and retinal detachment were predominant at the macula. The hemorrhagic pattern was characterized by hemorrhagic PED and macular subretinal hemorrhage. Eyes with PCV that did not undergo treatment had a variable course. About half of the eyes had a stable course and a relatively favorable outcome. The other half of the eyes had persistent leakage or repeated bleeding and a poor visual outcome. Sho et al. reported also severe visual loss incidence, which was 35% of PCV as compared to 53% in exudative AMD (Sho et al., 2003) .
5. Are PCV and neovascular AMD part of the same disease or are they distinct entities?
PCV associated with subretinal neovascularization was often mis-diagnosed using fluorescein angiography as wet age-related macular degeneration (AMD) (Laude et al., 2010; Lim et al., 2012) . Presently, it still remains unclear whether PCV represents a subtype of neovascularized AMD or a completely separate disorder. Both diseases share some similarities, like laterality (bilateral), presence of choroidal neovascularization and some genetic background (Laude et al., 2010) , however only based on the differences observed between the two diseases can, the proper diagnosis and treatment be performed (see Table 2 ). As stated above, the patients with PCV are mostly Asians or African-Americans and on the average they are younger than the patients diagnosed with AMD. Their eyes have considerably less, or even a complete lack of drusen, which are a characteristic sign of AMD (Laude et al., 2010) .
Although associated with multiple recurrent serosanguineous macular detachment, PCV is not linked to significant fibrous proliferation as is the case in end-stage neovascular AMD (Jager et al., 2008) . Choroidal thickness turns out to be different in the two disorders. As identified using enhanced-depth imaging optical coherence tomography, i.e. by the measurement of the vertical distance from the Bruch's membrane to the innermost scleral layer (Chung et al., 2011) , subfoveal choroidal thickness was thicker in the eyes with PCV, in contrast to the thinner choroid observed in eyes with AMD.
The relative importance of vascular endothelial growth factor (VEGF), an angiogenesis stimulator, and of pigment epithelium derived factor (PEDF), a protein that inhibits angiogenesis, both of which are expressed in choroidal neovascular membranes in eyes with PCV and AMD, also differs between the two diseases.
VEGF and PEDF were shown to be strongly expressed in vascular endothelial cells and retinal pigment epithelial cells of the excised subfoveal fibrovascular human CNV tissues (Matsuoka et al., 2004) . Although the expression level of VEGF is increased in both pathologies as compared to the healthy eye, the VEGF level in eyes diagnosed with PCV was considerable lower than in AMD eyes (Tong et al., 2006) . That may well be one of the reasons why the response to anti-VEGF treatment in PCV is not anywhere near as (Ojima et al., 2006; Tan et al., 2007). good as in AMD patients. Recently published SEVEN-UP trial data reporting on the seven-year outcome of ranibizumab-treated exudative AMD patients, confirmed that despite of the fact that one third of patients demonstrated good visual outcomes, another third had poor VA (Rofagha et al., 2013) . The conclusion of this study was that at this timepoint exudative AMD patients still remain at risk for substantial visual decline in the long term.
The histopathologic characteristics of PCV include hyalinized vessels, significant extravasation of plasma proteins lack of granulation tissue proliferation and deposition of basement membranelike material (Nakashizuka et al., 2008; Okubo et al., 2002) . Moreover, the foamy CD68-positive macrophages were reported around the vessel cavity, and HIF-1a positive mononuclear cells are present in the stroma. Immunoreactive VEGF deposits were present in the macrophages but not in the vascular endothelial cells. Hyalinized vessels in PCV are negative for a-SMA expression, although the pericytes of the vessels in CNV were immunoreactive for a-SMA.
This finding may indicate that the smooth muscle cells of choroidal vessels in PCV disappear due to the increased intraluminal pressure. CD34 staining revealed discontinuity in the vascular endothelium in the PCV.
For CNV secondary to AMD only a few CD68-positive cells are present in the stroma. HIF-1 positive mononuclear cells are located at macrophages and RPE cells but not at vascular endothelial cells. Calcification and fragmentation of Bruch's membrane was observed. Soft, and large drusen and basal laminar deposit are observed that strongly correlate with the histologic presence of AMD (Spraul et al., 1999) .
In PCV fibrosis and proliferation of RPE cells was more prominent than in CNV secondary to AMD. The fibrovascular tissue that appeared to correspond to the polypoidal lesions was observed under the RPE cells and contained numerous dilated, thin walled vessels and massive fibrin-like material (Matsuoka et al., 2004) .
The genetics of PCV and AMD has been extensively studied Cheng et al., 2013; Gotoh et al., 2009; Hayashi et al., 2010; Honda et al., 2012) . Age-related eye disease studies (AREDS) of AMD caseecontrol subjects using 100,000 single nucleotide polymorphisms (SNPs) resulted in the identification of four chromosomal regions significantly associated with the disease, i.e. the age-related maculopathy susceptibility 2(ARMS2)/Htra serine peptidase 1 (HTRA1) (10q26), the complement factor H (CFH) (1q32), the complement component 2/complement factor B (C2/BF, 6p21), and complement component 3 (C3, 19p13). It was hypothesized that overexpression of high temperature required factor A1 (HTRA1), which controls the integrity of Bruch's membrane, facilitates the invasion of Bruch's membrane by the CNV (Lee et al., 2008a) . The association between AMD, PCV and three SNPs in these gene regions rs1061170 (CFH), rs10490924 (ARMS2), and rs11200638 (HTRA1), were verified by a number of research groups both in Caucasians and Japanese patients (Goto et al., 2009; Kanda et al., 2007) . There is a consistent association of the ARMS2/HTRA1 locus with both neovascular AMD and PCV, suggesting the two diseases at least in part share molecular mechanisms (Cheng et al., 2013) ! HTRA1 was found to be associated with both disorders, being about two-fold stronger in AMD than in PCV (Lee et al., 2008a) in Asian patients. Another susceptibility gene in PCV is the elastin gene (ELN), which is shown to be more associated with PCV than with AMD (Kondo et al., 2008) . The LOC387715 rs10490924, i.e. the gene which codes mitochondrial protein in photoreceptors, was Zhang et al., 2011) found to be strongly associated with PCV and presented a different distribution in AMD and PCV . LOC387715 rs10490924 correlates with vitreous hemorrhage, and also with the lesion size. Rs10757278 on chromosome 9p21 was shown to be significantly associated with the risk of PCV in Chinese Han patients .
The role of thermal laser photocoagulation in the management of PCV
Few reports of laser photocoagulation for PCV have been described (Gomez-Ulla et al., 1998; Lafaut et al., 2000; Lee et al., 2009; Yuzawa et al., 2003) . Yuzawa et al. (2003) conducted laser photocoagulation for PCV, targeting only polypoidal lesions in 47 eyes. Intense photocoagulation, over a spot of 200 mm in diameter during 0.2 s induced a fusion scar. The irradiation was performed with an argon dye laser or multicolor krypton laser. 9 of 10 eyes that underwent photocoagulation, targeting the whole lesion, i.e. including both the network and polypoidal lesions, showed absorption of the exudate after a single treatment and maintained or improved vision without recurrence. 20 eyes (54%) showed decreased vision due to persistent, recurrent exudation and/or classic CNV, or alternatively due to RPE atrophy. In 32 eyes at least two, and sometimes more laser treatments were performed. Clearly multiple treatments were often needed, with longer followup, due to the recurrence of serosanguineous detachment originating from the remaining (or new) polypoidal lesions. Lafaut et al. (2000) treated 14 eyes with laser photocoagulation with follow up over 6 months. 10/14 eyes showed regression of fundus signs without persisting polyps. In the study of Lee et al. (Lee et al., 2009 ) from 28 eyes treated with argon laser photocoagulation, 10/28 showed improvement, 11/28 stabilization, 7/28 loss in the visual acuity outcome at final follow up after 12 months. At this time point 3/28 eyes had recurrence of polyps. Based on the recent guidelines for the management of PCV (Koh et al., 2013) , direct laser photocoagulation is not recommended as an initial therapy for subfoveal or juxtafoveal PCV, but it still may be used in the treatment of extrafoveal polyps (Koh et al., 2013; Lee et al., 2009 ).
Photodynamic therapy in PCV
The most effective treatment for polypoidal choroidal vasculopathy has not yet been completely established for all cases, but some trends can already be observed. Visudyne
clearly a safer treatment modality for subfoveal or juxtafoveal AMD and PCV than thermal laser photocoagulation, mainly due to the minimal damage done to the retina. PDT has consequently been used very successfully in treating PCV (Koh et al., 2012) . In the clinical reports on a single treatment of V Ò -PDT of PCV, with a follow-up of about 1 year, preservation and improvement of visual acuity was achieved in more than 80% of the mostly Asian patients (Imamura et al., 2010; Negrier and Raymond, 2012; . The summaries of these studies, which are discussed below, are presented in Table 3 . A prospective interventional study was performed on Japanese patients (Negrier and Raymond, 2012) . Based on indocyanine green angiography, 36 eyes (39%) were diagnosed with PCV and 54 eyes (58%) with choroidal neovascularization secondary to AMD. Visual recovery after V Ò -PDT was reported to be slightly more favorable for the eyes with PCV (8 letters) than in those with AMD (7.0 letters). The VA improved (15 letters or more) in 6% of the AMD patients, and in 25% of the PCV patients. The VA decreased (15 letters or more) in 31% of the AMD patients and in 8%, of the PCV patients.
At 1-year fluorescein leakage was suppressed in 86% of the PCV patients and 61% of the AMD eyes. In conclusion, V Ò -PDT resulted in superior results for treating PCV as compared to CNV secondary to AMD (Negrier and Raymond, 2012) in these patients. Spaide et al. (2012) , in a 1 year retrospective review, reported on 16 patients with subfoveal PCV treated with V Ò -PDT. The visual acuity improved in 9 (56.3%) of the patients, and remained the same in 5 (31.3%), and decreased in 2 (12.5%) of the patients. There were no reported long lasting complications after the treatment. The mean change in visual acuity was an improvement of nearly 2.4 lines! Promising results were also found in other studies in Japanese patients at 1 year after standard fluence V Ò -PDT ) or reduced-fluence V Ò -PDT (Yamashita et al., 2010 (Yamashita et al., , 2012 .
In both studies the PCV patients required a significantly lower retreatment PDT frequency, and also demonstrated a greater improvement in the visual acuity than was the case of the AMD patients, i.e. fewer PDT treatments per year were needed to obtain optimal results in the case of PCV than in the case of wet AMD. In patients with PCV treated with PDT, the recurrence period, i.e. the treatment-free period until the subsequent required intervention was significantly longer than was the case for wet AMD patients. Even though all polypoidal lesions regress with PDT, its effect on the branching network of polypoidal vessels does not seem to be permanent and thus recurrence of polypoidal lesions may occur in the long run. Another problem is the heterogeneous localization of the polyps, especially those in the peripapillary area, which is not always easily accessible to the laser-based PDT treatment. Repeated PDT in a minority of cases may induce persistent choroidal atrophy.
In another example, during a 3-year follow up period, a nonrandomized study was conducted involving eyes with newly diagnosed PCV, which were treated exclusively with V Ò -PDT (Leal et al., 2010) . Patients were submitted to an average of 3.19 treatment sessions. In this study, approximately 75% of the treated eyes had no significant loss of vision, and 14.8% showed significant improvement in visual acuity. Although the recurrences were frequent (59.3% of the eyes at 3 years of follow-up), they responded well to retreatment, and were not associated with increased visual acuity loss. Other limitations of PDT are occasional pigment epithelium detachment or the possibility of a large submacular hemorrhage. Hirami et al. (2007) retrospectively reviewed the data for 91 eyes of patients who underwent PDT for the treatment of PCV. In this study, during the follow-up period after PDT, postoperative subretinal hemorrhage was seen in 30.8% of eyes. In 78.6% of these eyes, the subretinal hemorrhage was absorbed without treatment. Although visual acuity was the same or increased in 81.8% of eyes with subretinal hemorrhage alone, it decreased significantly in 50.0% of the eyes with postoperative vitreous hemorrhage.
Akaza et al. with a follow-up of 24 months showed regression of the polypoidal lesions in 29 out of 31 eyes (94%). However, recurrence of polypoidal lesions appeared in 10 of 29 eyes (34%) and additional PDT was suggested. V Ò -PDT could reduce the size of polypoidal lesions, but did not destroy them completely. Thus, the persistent branching vessels in the network are supposed to be at the origin of the new polypoidal lesions (Akaza et al., 2008) . Idiopathic PCV is a disease with heterogeneous presentations, and the feeder vessel (FV) may be difficult to recognize. FV identification requires high-speed ICG (HSICG) identification in order to analyze blood flow dynamics in the feeder vessels and to select the optimal treatment area. For treatment of the feeder vessels (FV) associated with the CNV, V Ò -PDT was performed with a second light application, after applying the standard dose (50 J/cm 2 ) to the entire lesion (including a 1000 mm margin), with a second spot of around 200 mm diameter focused on the feeder vessel itself. This treatment did not lead to scotoma, and enabled to qualify the patient for a long-term follow up (Sickenberg M., unpublished data).
Similar results were obtained in another study with a follow-up of 19.2 months (Wakabayashi et al., 2008) . After initial V Ò -PDT, the polypoidal lesions regressed in 94% of eyes, but the branching vascular network remained in all eyes, and increased in size in 42% of eyes. Five-year follow up results on very small numbers of V Ò -PDT in Japanese patients with neovascular AMD and PCV seem to indicate that the difference in visual prognosis between AMD and PCV after long-term follow up was small (Tsuchihashi et al., 2013) . Previous reports with a follow up of 12 months showed significantly better results for PDT in the treatment of PCV, as compared to PDT for AMD. This long-term data on a very small number of patients indicated that there might not be that much difference in visual prognosis between AMD and PCV patients. PCV patients in this study had to have marginally more frequent retreatments in years 3 and 4 when compared to AMD patients. Rosenfeld et al. reported on the efficacy of standard fluence V Ò -PDT with delayed light application for exudative AMD (VALIO trial) (Rosenfeld et al., 2007) . There were no statistically significant differences between V Ò -PDT using the delayed light regimen of 30 min or the standard light regimen applied after 15 min. The efficacy of this approach, however, needs to be verified in PCV patients.
Summarizing, PDT in PCV demonstrated very positive short-to medium e term results. Retreatment is necessary in some cases, but at a relatively low frequency. PDT is currently the most effective and selective means of obliterating polypoidal lesions. The observations reported above prompted the search for strategies to improve the efficiency and selectivity of V Ò -PDT for polypoidal retinal lesions and reduce the treatment burden. It should be underlined here that the Visudyne Ò pharmacokinetic study by van den Bergh, Ballini and Sickenberg, showed enhanced selectivity between CNV and retinal capillaries at longer delays between injection and light application. However, normal choroidal capillaries were also closed by PDT together with the CNV. Further increase in the selectivity between choroidal and retinal vessels may also be obtained by shortening the duration of the Visudyne Ò injection.
However the desired improved targeting between CNV and choroidal capillaries will need a more sophisticated molecular approach.
Anti-VEGF therapy in PCV
The efficacy of the antievascular endothelial growth factor (VEGF) drug bevacizumab (Avastin Ò ; Genentech, South San Francisco, California, USA) is well known for treating CNV secondary to AMD (Avery et al., 2006) ; however, its efficacy for treating PCV seems limited (Imamura et al., 2010) . As reported by Gomi et al. 3 months after intravitreal bevacizumab, ICG angiography confirmed the reduced leakage from PCV but the treatment did not decrease the choroidal vascular changes. These results suggested that polypoidal dilation of choroidal vessels in PCV may not depend on VEGF to the same extent as does age-related neovascularization. This may be correlated with the observation that the VEGF levels in the aqueous humor in PCV are significantly lower than those in neovascular AMD (Tong et al., 2006) . The reasons for differences in anti-VEGF responsiveness in AMD and PCV are still not well understood. The angiogenic status of the tissue depends among others on the balance between proangiogenic VEGF and anti-angiogenic epithelium-derived growth factor (PEGF) (Gao et al., 2001) . Matsuoka et al. furthermore showed that when the subfoveal fibrovascular membranes are active, both VEGF and PEDF are strongly expressed in the endothelial cells. However, when the subfoveal fibrovascular membranes are in a more quiescent state, both VEGF and PEDF are barely expressed in the endothelial cells (Matsuoka et al., 2004) . This was also demonstrated in a preclinical model (the adult rat eye), where CNV was active. PEDF and VEGF were both strongly expressed in the choroidal neovascular lesions. After the CNV development was finished (i.e. quiescent CNV), the expression of both VEGF and PEDF decreased in the endothelial cells, whereas strong expression of PEDF was observed in the proliferating RPE cells covering the CNV (Ogata et al., 2002) .
Further studies have been performed with drugs that target other cytokines. One of these cytokines is platelet-derived growth factor (PDGF), a vascular maturation factor. The rationale behind the blocking of PDGF is to interfere with the process of vascular maturation via the reduction of pericyte recruitment and survival. The corresponding phase II trial, aiming to assess the efficacy and safety of a combination treatment regimen (E10030, which is anti-PDGF compound, plus ranibizumab), is ongoing. Macrophages are also involved in both AMD and PCV formation. Immunohistochemically, CD68-positive foamy macrophages have been detected around the hyalinized vessels, but a-smooth muscle actin (SMA)epositive cells were not. Hyalinized vessels in PCV were negative for a-SMA expression, although pericytes of vessels in CNV were immunoreactive for a-SMA (Nakashizuka et al., 2008) . These findings may indicate that smooth muscle cells of choroidal vessels in PCV disappear due to the increased intraluminal pressure.
Inflammation plays an important role in the pathogenesis of AMD. Thus immune components, such as complement factors, macrophages and cytokines are involved in the progression of AMD. Inflammation was observed, indicated by the presence of B and T lymphocytes, at the level of the choroid and the fibrovascular tissue and the significant presence of intercellular adhesion cytokines like ICAM-1 was shown. The choroidal infiltration by inflammatory cells was also reported by Rosa et al. (Rosa et al., 2002) . Therefore, anti-inflammatory agents, such as steroids, immunosuppressive agents or complement inhibitors may provide an adjuvant efficacy when combined with an anti-angiogenic strategy (Nowak-Sliwinska, 2012) in this disease.
Several studies reported decreased retinal thickness in PCV patients observed by OCT following intravitreal injection of bevacizumab (Ghajarnia et al., 2007; Lee et al., 2008b) . Kokame et al. wrote that multiple injections of monthly intravitreal ranibizumab, a humanized, full-length anti-VEGF antibody, were well tolerated in PCV patients. Additionally, patients also showed stabilized vision and decreased macular edema (Kokame et al., 2010) . Lai et al. evaluated the efficacy of intravitreal bevacizumab with or without V-PDT in the treatment of PCV with the mean follow-up duration of 12.8 months. Despite the visual and anatomical improvements, persistent polyps were present in ICGA of all eyes at 3 months (Lai et al., 2008) . There are also reports on patients with worsening exudation despite previous anti-VEGF therapy (Cho et al., 2009; Stangos et al., 2010) . Mahesh et al. reported on anti-VEGF treatment in 14 Indian patients with a follow up of 8 months. 12 patients received bevacizumab 1.25 mg, one patient received pegaptanib sodium 0.3 mg and one patient received 0.5 mg ranibizumab. All 14 patients had worsening of the clinical conditions after treatment and had to be retreated with thermal laser photocoagulation or reduced-fluence V Ò -PDT, depending on the location of these polyps. These data thus confirms the observed, inefficiency of anti-VEGF monotherapy in PCV. Summarizing, anti-VEGF monotherapy in PCV is not as efficient as it is in wet AMD, and requires the combination with other treatments like PDT or thermal laser photocoagulation.
Combination therapies in the treatment of PCV
PDT in combination with other treatment modalities for neovascular AMD has been extensively investigated in in vivo models and in clinical trials (Gomi et al., 2010; Lai et al., 2008; Saito et al., 2012; Weiss et al., 2012) . Angio-occlusive photodynamic therapy, besides the desired closing of the targeted CNV, also can damage and close the normal choroidal capillaries to some extent, thus causing both hypoxia and inflammation. This, in turn, can lead to reperfusion of the closed CNV, as well as regrowth of new CNV, and hence the necessity of retreatment. The closure of neovasculature by the combination of PDT with anti-angiogenic compounds thus can prevent recurrent neovascularization. Further addition of corticosteroids will help to prevent inflammation, and may provide an effective multilevel treatment for both AMD and PCV. Unique characteristics in the pathogenesis of PCV contribute to disease development and can be potential targets for intervention. To date, there is only limited information on combination therapy for PCV that is refractory to anti-VEGF therapy. The recent studies that show PCV being refractory to anti-VEGF therapy however suggest that the development of PCV is less likely, than for instance exudative AMD, to be strongly dependent on VEGF-related pathways. Bevacizumab was found to decrease the amount of exudation associated with PCV, but the results of this anti-VEGF monotherapy were not anywhere near as promising as those obtained in the treatment of wet AMD Imamura et al., 2010; Lai et al., 2008; Sridhar et al., 2013) . This is possibly due to the fact that in PCV one may deal with more mature vasculature than in the case of wet AMD, and there are genetic differences, like for instance in the elastin gene downregulation in AMD and upregulation in PCV, which may be related to the aneurysm-like polypoidal structures.
Kokame et al. in a trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV, reported the stabilization of vision at 6 months in 12 eyes (Kokame et al., 2010) , as well as resolution of subretinal hemorrhage and a decrease in macular edema. Moreover, polypoidal lesions decreased in 33% of eyes, but branching choroidal vessels were still present.
Presently, in order to investigate the safety and efficacy of a high dose ranibizumab (2.0 mg) in PCV patients, a phase II clinical trial (PEARL2) is recruiting patients (2010). The results are pending and are expected in 2013.
Due to the limited effectiveness of the anti-VEGF treatment by itself in PCV, combined therapy might be an option when persistent or recurrent exudative character of the lesions is observed post anti-VEGF treatments.
PDT and anti-VEGF targeting
In PDT of PCV, the mechanism of photothrombosis causes regression of the polyps and allows the gradual improvement of the pathological features. Combining PDT with an anti-VEGF agent can potentially create a synergistic effect that would (i) help to induce polyp regression, (ii) reduce fluid leakage and (iii) reduce inflammation. There are several studies reporting promising results on PDT combined with anti-VEGF treatment (see Fig. 5 for examples of OCT and color fundus images). Selected trials are summarized below and in Table 3 . The EVEREST trial was the only randomized controlled clinical trial including a set of well-defined ICGA criteria for PCV (Koh et al., 2012) . 61 Asian patients were randomized to either V Ò -PDT (standard fluence), or ranibizumab 0.5 mg, or the combination of the two. The primary endpoint was the proportion of patients with ICG-assessed complete regression of polyps at month 6. At Month 6, all three treatment groups showed visual acuity gain. In the ranibizumab monotherapy group, visual acuity improvements were observed despite the presence of polyps. This finding may be attributed to the anti-permeability effects of ranibizumab, thereby decreasing retinal thickening and exudate accumulation. V Ò -PDT combined with ranibizumab 0.5 mg or V Ò -PDT alone were both superior to ranibizumab monotherapy (77.8% and 71.4% vs. 28.6%, respectively) in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular PCV. Longer term studies with larger patient populations are required to assess the efficacy of the treatments in achieving complete regression of polyps and its correlation with visual acuity, and to evaluate the impact of concomitant V Ò -PDT or ranibizumab on decreasing the number of ranibizumab injections or V Ò -PDT interventions, respectively. In the study reported by Ruamviboonsuk et al. (Ruamviboonsuk et al., 2010) 12 eyes diagnosed with PCV were treated with V Ò -PDT combined with three monthly intravitreal ranibizumab (IVB) injections. The patients were monitored monthly with measurements of best-corrected visual acuity (BCVA) and OCT for 1 year. At that time point, the mean BCVA change from baseline was þ12.3 letters and in all patients regression of polyps without recurrence was observed. This combination therapy, however, did not reduce the number of patients who required re-treatment over the 1 year follow-up, when compared to data in the studies of V Ò -PDT alone. Also Gomi et al. reported superior results in PCV patients treated with V Ò -PDT combined with IVB injection (1.25 mg) as compared to patients treated with V Ò -PDT alone. The rate of development of subretinal hemorrhage within 1 month from the initial treatment was significantly lower in the combined therapy group than in the PDT monotherapy group. Combined treatment decreased the rate of PDT-related hemorrhage but did not affect the recurrence of the lesions (Gomi et al., 2010) . It is worth mentioning that the optimal time interval between intravitreal injection of anti-VEGF agents and PDT is still controversial. Sato et al. reported on efficient treatment of patients receiving 1.25 mg intravitreal bevacizumab 7 days prior to V Ò -PDT (Sato et al., 2010) where at 12 month the mean BCVA improvement from baseline was 2.69 lines. In a retrospectively reviewed study of 28 patients treated with 3 monthly intravitreal injections of ranibizumab (0.5 mg) and V Ò -PDT performed 1 or 2 days after the first injection of ranibizumab (Saito et al., 2012) and a follow up of 12 months, the mean visual acuity levels improved from 0.33 at baseline to 0.61. The mean improvement in best-corrected visual acuity from baseline was 2.65 lines, and the central retinal thickness decreased by two-fold. Administration of a ranibizumab injection 2 days before PDT achieved significantly better visual outcomes compared with administration of the injection 7 days before PDT (Sato et al., 2013) . Combined intravitreal ranibizumab and V Ò -PDT maintained or improved visual acuity and reduced the exudation without adverse events. In another trial, patients initially subjected to whole-lesion V Ò -PDT combined with IVB were retreated with reduced-fluence V Ò -PDT (at reduced spot size) þ IVB, or by thermal laser photocoagulation þ IVB (Jeon et al., 2013) . At year 3 after the first V ) combined with IVB (1.25 mg) was reported recently by Sagong et al. (Sagong et al., 2012) in sixteen patients with PCV. At 12 months, the visual acuity improved in 56% of the eyes by 3 lines or more, was stable in 37% of eyes, and decreased in 1 eye because of the recurrence of polyps. Reduced-fluence V Ò -PDT combined with IVB for PCV seemed to be effective in improving vision and reducing complications. Similar promising results were reported recently using reduced-fluence V Ò -PDT (light delivery over 70 s) followed 48 h later by intravitreal ranibizumab (0.5 mg) (Ricci et al., 2012) . Yoshida et al. (2013) reported on the 2-year results of reduced-fluence V Ò -PDT combined with intravitreal ranibizumab. The BCVAs were maintained in 13 of 14 PCV eyes at month 24 and the central foveal thickness was decreased. Summarizing, the combination therapy between Visudyne Ò -PDT and an anti-VEGF antibody or antibody fragment showed encouraging results including improved vision, the reduced incidence of subretinal hemorrhage, as well as the reduced recurrence of polyps when compared to PDT monotherapy for PCV. According to Koh et al. (Koh et al., 2013 ) the combination of V Ò -PDT with ranibizumab should be considered in eyes diagnosed with leakage from the branching vascular network and the polyps, and also for visible exudation associated with pigment epithelial detachment (PED). V Ò -PDT combined with ranibizumab should also be considered when ICGA results do not permit clearly to distinguish between PCV and CNV. The combination treatment would also ensure the optimal treatment in the cases of the co-existence of these two conditions (Brown et al., 2006; Koh et al., 2013) . Combination therapy efficacy might also depend on previous unsuccessful therapy and the possibility that resistance to the applied treatment developed (Tomita et al., 2012) . Thus PDT combined with ranibizumab led to significant visual recovery in treatment-naïve eyes with PCV, but not in eyes with PCV that had demonstrated recurrence after previous PDT.
PDT combined with anti-inflammatory compounds
PDT destroys existing neovessels effectively acting as a "CNV eraser", and can be combined with an anti-VEGF strategy aimed at inhibiting further neovessel growth and leakage. This combination can be further extended by the addition of corticosteroids, which will have an anti-inflammatory and anti-fibrosis effect. Thus, by affecting separate pathways it is not unreasonable to hope for possible synergies that lead to a better overall treatment outcome.
Whereas promising results of V Ò -PDT in combination with antiinflammatory compounds were reported in AMD , this treatment modality did not seem to be so efficient in PCV patients. A retrospective analysis of PCV patients who underwent V Ò -PDT with or without intravitreal triamcinolone acetonide (IVTA), with a follow-up of 2 or more years, was reported . Twenty-seven eyes were analyzed, with 12 eyes treated by PDT monotherapy and 15 eyes treated by combined V Ò -PDT with IVTA. PDT reduced the risks of visual loss in patients with symptomatic PCV in the short term, but the effect was not sustained after 1 year. The adjunctive use of IVTA during PDT did not appear to result in additional benefit in the PDT treatment of PCV.
Triple therapy
To date, there is only one report with a long-term evaluation of the combination therapy involving V Ò -PDT, anti-VEGF and an antiinflammatory agent (Nakata et al., 2013) for the treatment of PCV. The gain of visual acuity was reported in almost 42% of patients treated with the triple therapy, and only in 12% in the V Ò -PDT group. Moreover, in the triple therapy group, the retreatment-free period was longer and the vitreous hemorrhage was reduced as compared to that in the V Ò -PDT monotherapy group. Further longterm studies are necessary to optimize this promising triple therapy protocol for treating PCV.
Conclusions and future directions
Evidence based guidelines for the diagnosis and management of PCV have recently been published (Koh et al., 2013) . These guidelines include the use of indocyanine green angiography to identify the early phase nodular hyperfluorescence. The subsequent treatment for the juxtafoveal and subfoveal polyps is by ICG-guided PDT, possibly combined with three 0.5 mg ranibizumab injections, month apart, which is to be repeated if the polyps do not regress completely. The current opinion for optimal PCV treatment is based on clinical experience and a number of intermediate size case series. One question that remains is whether the more selective targeting of choroidal neovascular membranes would improve the therapeutic outcome of PDT, and thus lead leading to reduced retreatment rates (Madar-Balakirski et al., 2010) . The current use of PDT, both in AMD and PCV, is driven mainly by its combination with other treatment strategies, thus trying to affect distinctly separate pathways. An additional problem when making treatment decisions in PCV management is the branching vascular network that feeds the polyps. This branching vascular network can continue to persist or even proliferate after thermal laser treatment or photodynamic ablation of the polyps, and thus may finally cause new leakage.
Currently, a frequent strategy that appears in AMD clinical trials is the use of receptor tyrosine kinase inhibitors, e.g. pazopanib Direct interference with endothelial cell biology, independent of growth factor stimulation, is also a preferred strategy of antiangiogenesis. Volociximab, an a5b1 antagonist, is a high-affinity monoclonal antibody binding to a5b1 integrin. This compound blocks the binding of endothelial cells to fibronectin. A phase I trial to establish the safety, tolerability and the pharmacokinetics profile of Volociximab in CNV secondary to AMD is completed and results are pending (NCT00782093). JSM6427 is a small molecule antagonist selective for a5b1integrin. It is currently under evaluation in a Phase I clinical trial in patients with neovascular AMD (NCT00536016).
Another strategy is targeting the mammalian target of rapamycin (mTOR) with sirolimus. The mammalian target of rapamycin is a protein kinase that regulates cell growth and metabolism in response to changes in the environment. A phase II, randomized, multicenter study (EMERALD) is currently recruiting patients with wet AMD for a phase II study of an ocular sirolimus formulation in combination with ranibizumab (NCT00766337).
These above-mentioned studies show the situation in AMD treatment, however such data are not available for PCV. However, it would at least some of these trials may well be worthwhile repeating for the case of PCV. One of the problems in this case will be the absence of a valid animal model for PCV to do the preclinical evaluations.
Another way to effectively and selectively close neovascularization might be through treatment with vascular disrupting agents (VDAs) targeting tubulin. Tubulin is a protein dimer composed of a and b subunits that form microtubules, which are essential to cellular functions like mitosis, transport, and cytokinesis (McKeage and Baguley, 2010) . VDAs reversibly depolymerize the microtubules, leading to a shut down of the blood vessels. Zybrestat (Fosbretabulin, Oxigene Inc.) is a small molecule combretastatin-A4-phosphate prodrug that is converted to combretastatin inside endothelial cells. Once activated within the endothelial cells, it causes rapid collapse and necrosis of the vasculature. The FAVOR trial was a phase II study investigating the use of a single intravenous injection of Zybrestat at different doses (15e45 mg/m 2 ) compared to placebo in Asian patients with PCV, followed by imaging of the retina on days 2, 8,15, and 28. The primary objective of the study was to observe a change in the number of polyps from baseline following the administration of Zybrestat. The data showed that Zybrestat was well tolerated, however in the patients with decreased polypoidal activity, the reduction in subretinal fluid and retinal edema was insignificant (2012). Animal models of PCV still do not exist. Whereas part of the genotype has been reported on, there remain a number of problems. First, knockout mice with the known genotype alterations may not be subject to the same phenotypic disease severity as humans, which have a much longer lifespan. Second, the human eye's retina, with its high resolution color vision in the macula, where high light intensity signals are rapidly processed by cones, and the rest of the eye where rods dominate the lower resolution and low intensity night vision, is unlike the mouse's retina. Our retina furthermore has an extremely high density of photoreceptors, as well as a high photoreceptor/RPE cell ratio. Nevertheless, knock-in and knock-out animal models, with induced mutations, are expected in the near future to be of help in better understanding of the disease to be studied and the development of new treatments, as well as possible prevention strategies. One therapeutic approach to prevent possible causes of AMD or PCV may be the prevention of all-trans-RAL associated retinal degeneration. Preclinical studies conducted in a mouse model of light-induced retinal regeneration, in order to find selective inhibitors such as fenretinide and 13-cis-retinoic acid, or retinylamine, that can regulate the flux of retinoids through the visual cycle already gave promising results (Maeda et al., 2006; Radu et al., 2005) . One may speculate that such a strategy used for dry-type AMD, could possibly also help to prevent, or at least to some extent, slow down PCV development. The use of protective sunglasses and anti-oxidants should then also be considered, as better understanding of the effects of light on the eye would help to make a better choice of the interior light sources that to some extent can influence the development of eye disorders. Such an approach may help to, at least partially, prevent the progression of retinal dysfunction before visual acuity is affected.
In conclusion, photodynamic therapy with Visudyne Ò combined with anti-VEGF therapy represents, at this point of time, the best treatment modality for PCV. PCV is not as well treated by anti-VEGFs as is wet AMD. V Ò -PDT seems to work better in PCV than in wet AMD. V Ò -PDT in PCV gives good results for VA, suppressed leakage, as well as vessel disappearance. In newly diagnosed PCV patients who achieved initial positive responses (polyp regression) following V Ò -PDT only, additional treatment would not be required for at least 1 year for most of patients. For persistent or recurrent lesions, retreatment should be adapted to individual features since the branching network may be not destroyed completely. V Ò -PDT combined with anti-VEGFs works better for PCV than V Ò -PDT alone, or anti-VEGFs alone, giving good short-term results (up to two years). Still the photodynamic procedure itself might be improved by for instance the use of delayed light delivery after the Visudyne Ò injection.
Moreover, future molecular investigations are still needed to further identify the genetic differences between PCV and AMD. Also the relative timing of anti-VEGF and V Ò -PDT still needs to be optimized. According to preliminary data, same-day administration may result in less endophthalmitis and uveitis compared with treatments delivered days apart. It is worth emphasizing the EVEREST trail, where both V Ò -PDT and V Ò -PDT þ ranibizumab were efficient in achieving polyp regression. Triple therapy data seem to indicate that it offers a good safety profile, potentially lower cost, as compared with therapies that must be administered more frequently. More long-term investigation is needed to confirm its superiority vs. V 
